Published: 03 out 2024(Updated: 03 out 2024)
•60 min
•60 min read
•Olivia S. Shin, Stephanie R. Monticelli, Christy K. Hjorth, Vladlena Hornet, Michael Doyle, Dafna Abelson, Ana I. Kuehne, Albert Wang, Russell R. Bakken, Akaash K. Mishra, Marissa Middlecamp +Crimean-Congo hemorrhagic fever survivors elicit protective non-neutralizing antibodies that target 11 overlapping regions on glycoprotein GP38
Researchers at Adimab, LLC isolated 188 monoclonal antibodies against Crimean-Congo hemorrhagic fever virus (CCHFV) GP38 from human survivors. While non-neutralizing, these antibodies target 11 overlapping sites and demonstrate protective efficacy in rodent models. This study provides valuable insights into CCHFV viral glycoprotein and could aid the development of antibody therapeutics for this lethal virus.